Across TCGA pan-cancer cohorts, ENTPD4 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ENTPD4’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ENTPD4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ENTPD4 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where ENTPD4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ENTPD4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.598	<.001	6	view →
COAD	All	All	−0.238	.010	4	view →
LUAD	Female	III,IV	+0.378	.017	1	view →
PDAC	All	All	−0.378	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ENTPD4 RNA expression & survival · all ENTPD4 data types